Israel - English - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.

Israel - English - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

Israel - English - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

United States - English - NLM (National Library of Medicine)

jangin pharm co.,ltd. - peracetic acid (unii: i6kpi2e1hd) (peracetic acid - unii:i6kpi2e1hd) - multi disinfectant 1. sprinkle 20 cm away until moist 2.it is more effective if sprayed repeatedly every day.[storage precautions] store at room temperature(1-30 degrees celsius) [labeling items of household chemicals subject to safety verification]

United States - English - NLM (National Library of Medicine)

jangin pharm co.,ltd. - peracetic acid (unii: i6kpi2e1hd) (peracetic acid - unii:i6kpi2e1hd) - multi disinfectant 1. sprinkle 20 cm away until moist 2.it is more effective if sprayed repeatedly every day.[storage precautions] store at room temperature(1-30 degrees celsius) [labeling items of household chemicals subject to safety verification]

United States - English - NLM (National Library of Medicine)

jangin pharm co.,ltd. - peracetic acid (unii: i6kpi2e1hd) (peracetic acid - unii:i6kpi2e1hd) - multi disinfectant 1. sprinkle 20 cm away until moist 2.it is more effective if sprayed repeatedly every day.[storage precautions] store at room temperature(1-30 degrees celsius) [labeling items of household chemicals subject to safety verification]

United States - English - NLM (National Library of Medicine)

jangin pharm co.,ltd. - peracetic acid (unii: i6kpi2e1hd) (peracetic acid - unii:i6kpi2e1hd) - multi disinfectant 1. sprinkle 20 cm away until moist 2.it is more effective if sprayed repeatedly every day.[storage precautions] store at room temperature(1-30 degrees celsius) [labeling items of household chemicals subject to safety verification]

Australia - English - Department of Health (Therapeutic Goods Administration)

elitechgroup australia pty ltd - ct923 - multiple infectious organism ivds - ivds that are intended to be used in testing to provide information about mixed infection with or exposure to multiple specified infectious organisms from different microbial groups.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - somatropin, quantity: 10 mg/ml - injection, solution - excipient ingredients: histidine; phenol; poloxamer; mannitol; water for injections - children:treatment of growth failure in children due to pituitary growth hormone deficiency. treatment of growth failure in girls due to gonadal dysgenesis (turner's syndrome). treatment of growth failure in children due to chronic renal insufficiency whose height is on or less than the twenty-fifth percentile and whose growth velocity is on or less than the twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 30 ml/min/1.73 m2. treatment of severe growth failure due to intrauterine growth retardation (i.e., children born small for gestational age (birth weight and/or length < -2 sd) without spontaneous catch up growth by 2 years of age). adults: treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanogram/ml. in order to establish childhood onset [co] growth hormone insufficiency, reconfirmation by one provocative test is recommended. in order to establish isolated growth hormone deficiency two provocative tests are recommended. in adults, the insulin tolerance test is the provocative test of choice. when the insulin tolerance test is contraindicated, alternative provocative tests must be used. the combined arginine or the glucagon test may also be considered; however these tests have less established diagnostic value than the insulin tolerance test.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - somatropin, quantity: 6.67 mg/ml - injection, solution - excipient ingredients: poloxamer; mannitol; histidine; water for injections; phenol - children:treatment of growth failure in children due to pituitary growth hormone deficiency. treatment of growth failure in girls due to gonadal dysgenesis (turner's syndrome). treatment of growth failure in children due to chronic renal insufficiency whose height is on or less than the twenty-fifth percentile and whose growth velocity is on or less than the twenty-fifth percentile for bone age. chronic renal insufficiency is defined as glomerular filtration rate of less than 30 ml/min/1.73 m2. treatment of severe growth failure due to intrauterine growth retardation (i.e., children born small for gestational age (birth weight and/or length < -2 sd) without spontaneous catch up growth by 2 years of age). adults: treatment of adults with severe growth hormone deficiency as diagnosed in the insulin tolerance test for growth hormone deficiency and defined by peak growth hormone concentrations of less than 2.5 nanogram/ml. in order to establish childhood onset [co] growth hormone insufficiency, reconfirmation by one provocative test is recommended. in order to establish isolated growth hormone deficiency two provocative tests are recommended. in adults, the insulin tolerance test is the provocative test of choice. when the insulin tolerance test is contraindicated, alternative provocative tests must be used. the combined arginine or the glucagon test may also be considered; however these tests have less established diagnostic value than the insulin tolerance test.